Most drugs fail in early clinical stages because of a misaligned drug development strategy — one that underestimates the complexity of translating preclinical promise into human proof. Phase 1 and phase 2 trials expose every assumption made before the first patient is dosed: about the target, the molecule, the patient population, and the regulatory pathway. Understanding where and why strategies break down is the first step toward building one that holds.
What are the most common reasons drugs fail in phase 1 and phase 2 trials?
Drugs most commonly fail in phase 1 and phase 2 trials due to insufficient efficacy, unacceptable safety or tolerability, and poor pharmacokinetic profiles. These three categories account for the vast majority of early clinical attrition. Unlike late-stage failures, early failures often trace back to decisions made long before the first human dose.
Insufficient efficacy is the leading cause of phase 2 failure. A drug may show activity in a cell line or animal model but fail to demonstrate a meaningful clinical effect in humans, often because the preclinical models did not reflect the target disease biology accurately enough. Safety and tolerability issues, including off-target effects and dose-limiting toxicities, frequently emerge in phase 1 and can halt development before any efficacy signal is even established.
Pharmacokinetic failures, where the drug does not reach the target tissue at the right concentration for the right duration, are also common. Poor bioavailability, rapid clearance, or unexpected metabolism can undermine an otherwise promising compound. These are not random outcomes. They reflect gaps in the development strategy that were not addressed early enough.
How does a weak regulatory strategy contribute to early clinical failure?
A weak regulatory strategy contributes to early clinical failure by creating misalignments between the clinical program and what regulators actually require to evaluate safety and efficacy. When teams design trials without early regulatory input, they often generate data that is scientifically interesting but not decision-enabling from a regulatory standpoint.
Common regulatory strategy failures include submitting an Investigational New Drug application or Clinical Trial Application without a clearly defined clinical development plan, failing to align on primary endpoints that regulators consider clinically meaningful, and neglecting early scientific advice from agencies like the EMA or FDA. These oversights do not just slow programs down — they can force costly redesigns mid-trial or result in clinical holds. Teams that engage a knowledgeable regulatory consulting partner early in development are far better positioned to anticipate and navigate these pitfalls.
For complex products such as biologics, advanced therapy medicinal products, or drug-device combination products, the regulatory pathway itself is more intricate. Misclassifying a product or choosing the wrong regulatory route can invalidate months of clinical work. A robust regulatory strategy is not a compliance formality — it is a foundational input to every clinical decision made in early development.
Why does poor target selection derail drug development so early?
Poor target selection derails drug development early because the entire clinical program is built on the assumption that modulating a specific biological target will produce a meaningful therapeutic effect. If that assumption is wrong, no amount of clinical optimization will rescue the program.
Target selection failures often stem from over-reliance on single-species animal models, limited validation of the target’s role in human disease, or failure to account for patient population heterogeneity. A target that drives disease in one subset of patients may be irrelevant in another, which is why biomarker-driven patient stratification has become increasingly important in early-stage oncology and immunology programs.
The challenge for early-stage companies is that target validation is resource-intensive, and there is pressure to advance quickly to preserve runway and investor confidence. Cutting corners on target biology to accelerate timelines is one of the most expensive shortcuts in drug development. Investing in rigorous target validation before entering the clinic dramatically improves the probability of generating a meaningful phase 2 signal.
What role does clinical trial design play in early-stage failures?
Clinical trial design plays a critical role in early-stage failures because a poorly designed trial can produce uninterpretable results even when the drug itself has genuine therapeutic potential. The wrong endpoints, an underpowered study, or an inappropriate patient population can make an effective drug look like a failure.
Several design elements are especially consequential in early clinical development:
- Endpoint selection: Using surrogate endpoints that are not validated or not accepted by regulators creates risk. Primary endpoints must be clinically meaningful and measurable within the trial’s timeframe.
- Patient population definition: Broad inclusion criteria can dilute the treatment effect in a subpopulation where the drug actually works. Enrichment strategies and biomarker-defined populations improve signal detection.
- Dose selection: Phase 1 dose escalation decisions directly inform phase 2 dosing. Selecting a dose that is too low to show effect, or too high to be tolerable, can terminate a program prematurely.
- Adaptive design: Rigid trial designs that cannot respond to emerging data waste time and resources. Adaptive elements, such as interim analyses with pre-specified stopping rules, allow faster and more efficient decision-making.
Getting trial design right requires close collaboration between clinical, statistical, and regulatory teams from the outset. It is not a document produced after the science is done — it is part of the science.
How can companies identify and fix a failing drug development strategy early?
Companies can identify a failing drug development strategy early by conducting structured go/no-go reviews at defined decision points, using pre-specified criteria to evaluate whether the program is generating the evidence needed to support advancement. The key is building these checkpoints into the plan before development begins, not reacting to problems after they surface.
Early warning signs of a deteriorating strategy include: a growing disconnect between preclinical and early clinical data, regulatory feedback that questions the clinical rationale, difficulty enrolling the target patient population, and dose-response data that does not support the proposed therapeutic window. Any one of these signals warrants a formal strategy reassessment.
Fixing a failing strategy requires honest prioritization. Teams should ask whether the target is genuinely validated in humans, whether the regulatory pathway is clearly defined, and whether the trial design is capable of generating decision-enabling data. In some cases, the right answer is to reposition the asset for a different indication, narrow the patient population, or seek early scientific advice from regulators before committing further resources.
External regulatory and clinical expertise can be particularly valuable at these inflection points. An independent perspective often surfaces blind spots that internal teams, under pressure to advance, may have rationalized away. Learning more about the background and approach of your advisory partner before engaging can help ensure the expertise on offer genuinely matches your program’s needs.
How Starodub supports your drug development strategy
At Starodub, we work with biopharmaceutical companies at every stage of early clinical development to ensure that regulatory strategy is built into the program from day one, not bolted on after problems emerge. Our team brings hands-on experience with small molecules, biologics, ATMPs, and combination products across EMA and global regulatory frameworks.
Here is what we provide:
- Regulatory pathway assessment: We evaluate your product’s classification, applicable guidelines, and the most efficient route to clinical authorization, including CTA preparation and scientific advice procedures.
- CMC regulatory strategy: We align your chemistry, manufacturing, and controls documentation with regulatory expectations at each development phase, preventing data gaps that can delay or derail applications.
- Clinical trial application support: We prepare and manage CTA submissions across EU member states, ensuring your trial design and supporting data meet current regulatory standards.
- Regulatory gap analysis: We identify weaknesses in existing development plans and provide concrete recommendations before they become costly problems in the clinic.
- Ongoing compliance support: Through our quality management system aligned with GxP and ISO standards, we provide structured oversight throughout your clinical program.
If your drug development strategy needs a regulatory foundation that can withstand early clinical scrutiny, we are ready to help. Contact Starodub today to discuss your program and find out how we can support your path to clinical proof of concept.
Related Articles
- When should a biotech company pursue orphan drug designation?
- How do you maintain GMP compliance during a facility expansion?
- How do you measure the effectiveness of a GMP compliance program?
- How does South Korea's HIRA reimbursement process work?
- How do you handle regulatory compliance for AI-powered medical devices?
This content was generated with the help of AI and it may contain mistakes
